Product Program year 2022 Source: CMS Open Payments

Northera

Drug Neurology

NDC 67386-820-19

Open in the dashboard

General payments

$1,568,290

16,391 payments

Research payments

$3,524,377

1,046 payments

Through program year 2022, $1,568,290 in general payments and $3,524,377 in research payments were reported against Northera (Neurology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Amount Payments
2022 General $13,450 5
2022 Research $442,210 245
2021 General $44,035 1,422
2021 Research $726,800 338
2020 General $342,269 4,206
2020 Research $980,049 349
2019 General $1,168,535 10,758
2019 Research $1,375,318 114

Breakdown

Who paid General payments · program years 2019–2022
  1. Lundbeck LLC $1,554,439 16,378 payments
  2. H. Lundbeck A S $13,851 13 payments
Top recipients General payments · program year 2022
  1. William White Hypertension Specialist · Farmington, CT $9,750 72% · 2 payments
  2. Aristide Merola Neurology · Columbus, OH $2,200 16% · 1 payment
  3. Stewart Factor Neurology · Atlanta, GA $1,500 11% · 2 payments

Each share is of general payments naming this product in 2022.

Specialties paid General payments · program year 2022
  1. Hypertension Specialist Internal Medicine $9,750 72% · 1 practitioner
  2. Neurology Psychiatry & Neurology $3,700 28% · 2 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2022
  1. Connecticut $9,750 72% · 1 recipient
  2. Ohio $2,200 16% · 1 recipient
  3. Georgia $1,500 11% · 1 recipient

Each share is of general payments naming this product in 2022 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

467

Prescriptions dispensed, refills included

Drug cost

$7,040,346

Paid at the pharmacy, in all

Prescribers

33

With 11 or more claims of it

Medicare Part D drugs matched to NORTHERA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Northera Droxidopa Same name 33 467 $7,040,346

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 33 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Marina Neystat Neurology NY 70 $1,123,077 None on record
Ahmet Gursoy Interventional Cardiology FL 18 $197,801 None on record
William Scharle Family Practice PA 15 $53,942 None on record
Michal Gostkowski Neurology OH 14 $152,691 None on record
James Muldowney Cardiology TN 14 $141,708 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 33 with Patron
16,391 general · 1,046 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record